Loading Events

UroGen Pharma to Present 12-Month DOR Data from the Phase 3 ENVISION Pivotal Trial of UGN-102 in Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) at a Virtual Event

Banners-9
DATE: June 13, 2024
TIME: 11:00 AM EDT
LOCATION: Virtual

About The Event

This event has passed.

Join UroGen Pharma for a virtual event featuring Jennifer Linehan, MD (Saint John’s Cancer Institute), Angela Stover, PhD (UNC Gillings School of Global Public Health), Max Kates, MD (Johns Hopkins School Of Medicine), James McKiernan, MD (Columbia University Irving Medical Center) and Sandip Prasad, MD (Morristown Medical Center/Atlantic Health System) to present 12-month Durability of Response results from the Phase 3 ENVISION pivotal trial of UGN-102 (mitomycin) for intravesical solution for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

Company management and guests will provide an overview of the current treatment landscape for patients with LG-IR-NMIBC and discuss the role of UGN-102 as a groundbreaking potential new treatment offering a nonsurgical alternative to the transurethral resection of bladder tumor (TURBT) standard of care.

A live question and answer session will follow the formal presentation.